Operating CF
$2.59B
Capex
$32.30M
Free Cash Flow
$2.62B
FCF Margin
+101.2%
Cash flow waterfall for Biogen (BIIB) — TTM through Q1 2026
Free cash flow: $2.62B
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for Biogen (BIIB) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $2.59B | $2.59B |
| Capital Expenditure | $32.30M | $2.62B |
| Free Cash Flow | $2.62B | $2.62B |
| Other Investing | −$1.57B | $1.06B |
| Other Financing | −$322.60M | $735.00M |
| Forex Effect | $49.60M | $784.60M |
| Net Cash Increase | $782.10M | $782.10M |
- Operating Cash Flow$2.59B
- Capital Expenditure$32.30M
- Free Cash Flow$2.62B
- Other Investing−$1.57B
- Other Financing−$322.60M
- Forex Effect$49.60M
- Net Cash Increase$782.10M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement